LinkedIn

„First-generation precision therapeutics are already making a big difference for patients with limited available options in today’s clinical practice, but I am convinced that a new era of targeted therapeutics is just starting, and Navigo Proteins is superbly positioned to provide the essential components of next-generation immunology and oncology products.”

Chris joined Navigo Proteins in February 2022 as Chief Development Officer (CDO) and is responsible for the development of Affilin®-based biotherapeutics. He has over 20 years of experience in Commercial roles, Business Development, Partnering and Product Development with an education as Medical Doctor and MBA. Before joining Navigo Chris worked for the Grünenthal Group in roles such as Commercial Director, Senior Vice President Marketing and Executive Vice President Early Products.